Top Research Reports for Visa, AbbVie & Analog Devices

Wednesday, January 15, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Analog Devices, Inc. (ADI), as well as a micro-cap stock Precipio, Inc. (PRPO).  The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past six months (+15.2% vs. +14.7%). The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving revenues. The company, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth.The Zacks analyst expects revenues to grow 9.1% in fiscal 2025. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.However, elevated operating expenses pose margin challenges. We expect adjusted operating expenses to jump 8.1% in fiscal 2025. It is witnessing a volatile cash volume from the Asia Pacific and U.S. regions. Consumer spending growth is also drying up. Moreover, rising client incentives will affect its adjusted revenues.(You can read the full research report on Visa here >>>)Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+11.7% vs. -2.2%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq. The drugs are performing extremely well, bolstered by approvals in new indications.AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. AbbVie has been on an acquisition spree lately in its core space of immunology.However, the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth for Juvederm fillers in the United States and China. AbbVie’s shares have outperformed the industry in the past year. Estimates have declined slightly ahead of Q4 earnings.(You can read the full research report on AbbVie here >>>)Analog Devices’ shares have outperformed the Zacks Semiconductor - Analog and Mixed industry over the past year (+16.3% vs. +0.2%). The company is benefiting from strong momentum across the consumer and automotive end markets. Strong momentum across the electric vehicle space on the back of its robust Battery Management System solutions remains a tailwind.Strong investments in technology and business innovation are contributing well. The solid momentum of the HEV platform across the cabin electronics ecosystem is positive.Nonetheless, the weak demand environment across multiple end markets remains a major concern. The sluggish communications market due to the broad-based inventory corrections is a major negative. Broad-based weakness in the industrial end market remains a headwind. The ongoing inventory correction is expected to be a headwind for the company in the near term.(You can read the full research report on Analog Devices here >>>)Shares of Precipio have outperformed the Zacks Medical Info Systems industry over the past year (+15.0% vs. -12.1%). This microcap company with market capitalization of $8.98 million have achieved breakeven in its Pathology arm for two consecutive quarters in 2024, generating $4.6 million in third-quarter revenues, up 17.7% from the second quarter. Its $20 million annual run rate provides stable cash flow to fund R&D without external capital, highlighting operational efficiency.The Products arm, with 13.9% third-quarter revenue growth, is poised as a high-margin growth engine, leveraging scalable distribution channels. Cash burn fell 75% year over year to $226,000 in the third quarter, supporting financial stability and non-dilutive growth.Precipio’s focus on diagnostics innovation, digital transformation and market visibility aligns with precision medicine trends. Risks include Products underperformance, reliance on small sales teams, distributor dependency, competitive pressures, macroeconomic factors and regulatory uncertainties.(You can read the full research report on Precipio here >>>)Other noteworthy reports we are featuring today include UnitedHealth Group Inc. (UNH), Constellation Energy Corp. (CEG) and Equinor ASA (EQNR).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadVisa (V) Rides on Increasing Payments Volume, Expenses HighAbbVie's (ABBV) Skyrizi, Rinvoq Key to Top-Line GrowthAnalog Devices (ADI) Gains From Traction in its Automotive ProductsFeatured ReportsUnitedHealth (UNH) to Ride on UnitedHealthcare & Optum UnitsPer the Zacks analyst, UnitedHealth's strong performance in UnitedHealthcare and Optum businesses will lead to increased profits. Yet, rising operating expenses remain a concern.Focus on Renewable Energy Aid Constellation Energy (CEG)Per the Zacks analyst, Constellation Energy gains from expansion of renewable portfolio. Its position as an industry leader in the safe operation of nuclear plants helps it increase its nuclear outputInvestment in Clean Assets Aid Public Service Enterprise (PEG)Per the Zacks analyst, Public Service Enterprise makes investments to strengthen its infrastructure and expand renewable assets, which are going to boost its operation.Corning (GLW) Rides on Healthy Demand & Product InnovationPer the Zacks analyst, the growing adoption of innovative optical connectivity products for generative AI applications and strong demand for Gorilla Glass will likely drive Corning's top line.Waters' (WAT) Rides on Strong Demand for Testing SolutionsWaters is benefiting from an expanding portfolio, improving pharma spending bodes and strong demand for flagship HPLC product.Aerospace Segment & MB Aerospace Buyout Drives Barnes (B)Per the Zacks analyst, Barnes is witnessing strength in the Aerospace aftermarket unit, fueled by higher airline traffic & aircraft utilization. The MB Aerospace buyout contributes strongly to growth.Potential in BioReference Business Aids OPKO Health (OPK)The Zacks analyst is upbeat about OPKO Health's strength in BioReference Health, offering comprehensive laboratory testing services, despite its operation in a highly competitive space.New UpgradesEquinor's (EQNR) Focus on Renewable Energy Expansion AidsThe Zacks analyst believes that Equinor's expansion in the renewables and low-carbon energy sector should create new revenue streams in the growing market for clean energy.Extensive Footprint & Omnichannel Efforts Aid Carmax (KMX)Per the Zacks analyst, CarMax's extensive nationwide footprint and logistics network provides it a competitive advantage. Omnichannel initiatives are set to boost its long-term efficiencies.Loan Diversification, Rising Deposit Aid First Horizon (FHN)Per the Zacks analyst, First Horizon's organic growth is supported by its diversified loan portfolio. Additionally, the rising deposit balance further contributes to top-line expansion.New DowngradesFreight Demand Weakness Hurts Werner's (WERN) Prospects The Zacks analyst is concerned about Werner's below-par revenues due to weak freight demand. Driver shortage represents another headwind for WERN.Signet (SIG) Struggles with Fashion Gifting as Comps DeclinePer the Zacks analyst, Signet saw a drop in same-store sales, with the fashion gifting segment underperforming due to shifting consumer preferences for lower-priced items. The company cut the Q4 view.High Expenses & Market Risks Ail Builders FirstSource (BLDR)Per the Zacks analyst, Builders FirstSource is hurting from a reduced operating leveraging resulting in high expenses. Moreover, the inflationary pressures and market fluctuations are adding to it.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Analog Devices, Inc. (ADI): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Constellation Energy Corporation (CEG): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Precipio, Inc. (PRPO): Free Stock Analysis Report Equinor ASA (EQNR): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks